Business Wire helped CiceroDx, Inc. to announce the publication of a new study that demonstrates the effectiveness of treatment in unexplained infertility patients with abnormal endometrial BCL6 expression. The study supports the growing empirical evidence showing the relationship of BCL6 expression with endometrial inflammation and suspected endometriosis.
The results showed a significant increase in the clinical pregnancy rate and live birth rate for treatments of patients who tested positive for BCL6. For these patients, the miscarriage rate also saw a significant decrease.
The study gives thousands of women with unexplained infertility new hope and a new pathway to success, potentially saving thousands of dollars on IVF cycles by identifying patients in advance with low likelihood of IVF success if left untreated.
To learn more about the study and to read the full article on Business Wire, click here.